Safety Profile

Comparable Safety Profile: FASLODEX 500 mg vs FASLODEX 250 mg1

The CONFIRM study results showed a comparable safety profile when comparing FASLODEX 500 mg to FASLODEX 250 mg.

Most commonly reported adverse events (≥5% in either treatment group)

FASLODEX® (fulvestrant) Injection 500 mg vs 250 mg CONFIRM Study Most Commonly Reported Adverse Events

  • 2 patients (0.6%) receiving FASLODEX 500 mg and 3 patients (0.8%) receiving 250 mg discontinued due to drug-related adverse events5
  • Patients received the same number of injections1
    • FASLODEX 500-mg arm received 2 x 250-mg injections on days 1, 15, and 29 and once monthly thereafter
    • FASLODEX 250-mg arm received 1 x 250-mg injection plus one placebo injection on days 1, 15 (2 placebo injections only), and 29 and once monthly thereafter
  • Increased hepatic enzymes (AST, ALT, ALP) occurred in >15% of FASLODEX users and were non dose-dependent
View the data for efficacy

FASLODEX is indicated for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.

IMPORTANT SAFETY INFORMATION:
FASLODEX is contraindicated in patients with known hypersensitivity to the drug or to any of its components. Hypersensitivity reactions, including urticaria and angioedema have been reported in association with FASLODEX.

Click Here for Additional Safety Information

OnCue - News for
oncology professionals

Regularly updated articles cover a range of topics including treatment information, oncology conferences details, and patient resources.

Visit OnCueFeed.com

AZ ProCare Webcasts

Hear from disease-state experts about the treatment and management of HR+ metastatic breast cancer through live and archived Webcasts.

Visit AZProCare.com